Moderna uncloaks 'profound' immune-evading mRNA therapeutic platform
This article was originally published in Scrip
Executive Summary
Moderna Therapeutics has raised an impressive $40 million-plus in its first 18 months to fund technology that represents a profound change from established biological manufacturing - messenger RNA (mRNA) injected into the body and taken up by cells whose ribosomes then use the mRNA to produce therapeutic intra-cellular or secreted proteins.
You may also be interested in...
Moderna's Vaccine Portfolio Primed For Boost From Its COVID-19 Work
At its "Vaccines Day" with investors, Moderna execs tout the company's messenger RNA platform and say its portfolio of vaccine candidates has the potential to reach annual peak sales of up to $12bn.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.